Investigational New Drug CDMO Market Size, Trends, Analysis, and Outlook By Product (Small Molecule, Large Molecule), By Service (By Small MoleculeContract Development (Bioanalysis and DMPK studies, Toxicology Testing, Pathology and safety pharmacology st

Investigational New Drug CDMO Market Size, Trends, Analysis, and Outlook By Product (Small Molecule, Large Molecule), By Service (By Small MoleculeContract Development (Bioanalysis and DMPK studies, Toxicology Testing, Pathology and safety pharmacology studies, Drug substance synthetic route development, Drug substance process development, Form selection crystallization process development, Scale-up of drug substance, Preformulation, Preclinical formulation selection, First in Man Formulation/Process Development, Analytical method development/validation, Release testing of drug substance and drug product, Work up Purification Steps, Telescoping & Process Refining, Initial Optimization, Formal stability of drug substance and drug product), By Large Molecule Contract Development (Cell Line development, Process Development), By Small Molecule Contract Manufacturing (Oral Solids, Liquid and Semi-solids, Injectables, Others), By Large Molecule Contract Manufacturing (MABs, Recombinant proteins, Others), By End-User (Pharmaceutical Companies, Biotech Companies, Others), by Region, Country, Segment, and Companies, 2024-2030

The global Investigational New Drug CDMO market size is poised to register 7.28% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Investigational New Drug CDMO market across By Product (Small Molecule, Large Molecule), By Service (By Small MoleculeContract Development (Bioanalysis and DMPK studies, Toxicology Testing, Pathology and safety pharmacology studies, Drug substance synthetic route development, Drug substance process development, Form selection crystallization process development, Scale-up of drug substance, Preformulation, Preclinical formulation selection, First in Man Formulation/Process Development, Analytical method development/validation, Release testing of drug substance and drug product, Work up Purification Steps, Telescoping & Process Refining, Initial Optimization, Formal stability of drug substance and drug product), By Large Molecule Contract Development (Cell Line development, Process Development), By Small Molecule Contract Manufacturing (Oral Solids, Liquid and Semi-solids, Injectables, Others), By Large Molecule Contract Manufacturing (MABs, Recombinant proteins, Others), By End-User (Pharmaceutical Companies, Biotech Companies, Others).

The investigational new drug (IND) CDMO market is experiencing significant growth driven by the increasing outsourcing of early-phase drug development activities, rising demand for specialized expertise and infrastructure, and advancements in contract manufacturing capabilities. In 2024 and beyond, factors such as the growing pipeline of novel biologics and small molecules, expansion of virtual and small biotech companies, and rising emphasis on cost-effective drug development drive market expansion. Additionally, the development of integrated IND development platforms, expansion of analytical and formulation services, and partnerships between CDMOs and pharmaceutical sponsors contribute to market growth.

Investigational New Drug CDMO Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Investigational New Drug CDMO market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Investigational New Drug CDMO survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Investigational New Drug CDMO industry.

Key market trends defining the global Investigational New Drug CDMO demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Investigational New Drug CDMO Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Investigational New Drug CDMO industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Investigational New Drug CDMO companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Investigational New Drug CDMO industry

Leading Investigational New Drug CDMO companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Investigational New Drug CDMO companies.

Investigational New Drug CDMO Market Study- Strategic Analysis Review

The Investigational New Drug CDMO market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Investigational New Drug CDMO Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Investigational New Drug CDMO industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Investigational New Drug CDMO Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Investigational New Drug CDMO Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Investigational New Drug CDMO market segments. Similarly, Strong end-user demand is encouraging Canadian Investigational New Drug CDMO companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Investigational New Drug CDMO market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Investigational New Drug CDMO Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Investigational New Drug CDMO industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Investigational New Drug CDMO market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Investigational New Drug CDMO Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Investigational New Drug CDMO in Asia Pacific. In particular, China, India, and South East Asian Investigational New Drug CDMO markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Investigational New Drug CDMO Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Investigational New Drug CDMO Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Investigational New Drug CDMO market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Investigational New Drug CDMO.

Investigational New Drug CDMO Market Company Profiles

The global Investigational New Drug CDMO market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Cambrex Corp, Catalent, Charles River Laboratories Inc, Covance Inc, IQVIA Holdings Inc, Lonza, Recipharm AB, Siegfried Holding AG, Syneos Health, Thermo Fisher Scientific Inc

Recent Investigational New Drug CDMO Market Developments

The global Investigational New Drug CDMO market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Investigational New Drug CDMO Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Product

Small Molecule

Large Molecule

By Service

By Contract Development (Small Molecule)

Bioanalysis and DMPK studies

Toxicology Testing

Pathology and safety pharmacology studies

Drug substance synthetic route development

Drug substance process development

Form selection crystallization process development

Scale-up of drug substance

Preformulation

Preclinical formulation selection

First in Man Formulation/Process Development

Analytical method development/validation

Release testing of drug substance and drug product

Work up Purification Steps

Telescoping & Process Refining

Initial Optimization

Formal stability of drug substance and drug product

By Contract Development (Large Molecule)

Cell Line development

Process Development

-Upstream

-Downstream

By Contract Manufacturing (Small Molecule)

Oral Solids

Liquid and Semi-solids

Injectables

Others

By Contract Manufacturing (Large Molecule)

MABs

Recombinant proteins

Others

By End-User

Pharmaceutical Companies

Biotech Companies

Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies

Cambrex Corp

Catalent

Charles River Laboratories Inc

Covance Inc

IQVIA Holdings Inc

Lonza

Recipharm AB

Siegfried Holding AG

Syneos Health

Thermo Fisher Scientific Inc

Formats Available: Excel, PDF, and PPT